MX2017013047A - Tratamiento de dolor. - Google Patents

Tratamiento de dolor.

Info

Publication number
MX2017013047A
MX2017013047A MX2017013047A MX2017013047A MX2017013047A MX 2017013047 A MX2017013047 A MX 2017013047A MX 2017013047 A MX2017013047 A MX 2017013047A MX 2017013047 A MX2017013047 A MX 2017013047A MX 2017013047 A MX2017013047 A MX 2017013047A
Authority
MX
Mexico
Prior art keywords
pain
treatment
imidazo
tetrahydro
carboxylate
Prior art date
Application number
MX2017013047A
Other languages
English (en)
Inventor
Richardson Peter
Gonzalez Isabel
Pritchard Martyn
Original Assignee
Proximagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proximagen Ltd filed Critical Proximagen Ltd
Publication of MX2017013047A publication Critical patent/MX2017013047A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

(4S)-4-isopropil-1,4,6,7-tetrahidro-5H-imidazo-[4,5-c]-piridin-5- carboxilato de (3S)-tetrahidrofuran-3-ilo, y sales del mismo para uso en el tratamiento de dolor.
MX2017013047A 2015-04-24 2016-04-22 Tratamiento de dolor. MX2017013047A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1507048.5A GB201507048D0 (en) 2015-04-24 2015-04-24 Treatment of pain
PCT/GB2016/051122 WO2016170353A1 (en) 2015-04-24 2016-04-22 Treatment of pain

Publications (1)

Publication Number Publication Date
MX2017013047A true MX2017013047A (es) 2017-12-08

Family

ID=53488643

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013047A MX2017013047A (es) 2015-04-24 2016-04-22 Tratamiento de dolor.

Country Status (22)

Country Link
US (1) US20180104223A1 (es)
EP (1) EP3285767B8 (es)
JP (2) JP2018520984A (es)
KR (1) KR20170139047A (es)
CN (1) CN107530330A (es)
AU (1) AU2016252237B2 (es)
BR (1) BR112017019337A2 (es)
CA (1) CA2979160A1 (es)
DK (1) DK3285767T3 (es)
EA (1) EA032512B1 (es)
ES (1) ES2720035T3 (es)
GB (1) GB201507048D0 (es)
HK (1) HK1249865B (es)
HU (1) HUE043871T2 (es)
IL (1) IL254155B (es)
MX (1) MX2017013047A (es)
PL (1) PL3285767T3 (es)
PT (1) PT3285767T (es)
SG (1) SG11201707870SA (es)
TR (1) TR201905392T4 (es)
WO (1) WO2016170353A1 (es)
ZA (1) ZA201705847B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201304526D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
GB201507031D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd New pharmaceutical salt forms
GB201507036D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Crystalline enzyme inhibitor compound
EP3386494A1 (en) * 2015-12-07 2018-10-17 Benevolentai Cambridge Limited Vap-1 inhibitors for treating pain
GB201618029D0 (en) * 2016-10-25 2016-12-07 Proximagen Ltd New process
GB201709136D0 (en) * 2017-06-08 2017-07-26 Proximagen Ltd New therapeutic uses of enzyme inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4055593A (en) * 1992-05-15 1993-12-13 University Of Saskatchewan Method for preventing endothelium damage in mammals and for alleviating pain associated with gout and arthritis
JP2008512346A (ja) * 2004-09-09 2008-04-24 アステラス製薬株式会社 Ｖａｐ−１阻害活性を有するチアゾール誘導体
US20070066646A1 (en) * 2005-08-02 2007-03-22 Genmedica Therapeutics Sl Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof
EP3042668B1 (en) 2006-06-07 2018-09-19 The Board of Trustees of the Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy
TWI490214B (zh) * 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
EP2334672B1 (en) * 2008-09-16 2013-11-20 Proximagen Limited 4,5,6,7-Tetrahydroimidazo[4,5-c]pyridine compounds as inhibitors of SSAO
FI20115234A0 (fi) * 2011-03-08 2011-03-08 Biotie Therapies Corp Uusia pyridatsinoni- ja pyridoniyhdisteitä
CA2915163A1 (en) * 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
US9790193B2 (en) * 2014-04-15 2017-10-17 Pécsi Tudományegyetem Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation
GB201507031D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd New pharmaceutical salt forms
GB201507036D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Crystalline enzyme inhibitor compound

Also Published As

Publication number Publication date
US20180104223A1 (en) 2018-04-19
WO2016170353A1 (en) 2016-10-27
BR112017019337A2 (pt) 2018-06-05
CN107530330A (zh) 2018-01-02
SG11201707870SA (en) 2017-11-29
KR20170139047A (ko) 2017-12-18
EP3285767B1 (en) 2019-03-20
IL254155B (en) 2021-02-28
PL3285767T3 (pl) 2019-09-30
EP3285767A1 (en) 2018-02-28
ES2720035T3 (es) 2019-07-17
CA2979160A1 (en) 2016-10-27
AU2016252237B2 (en) 2021-04-08
HUE043871T2 (hu) 2019-09-30
IL254155A0 (en) 2017-10-31
HK1249865B (zh) 2019-12-06
DK3285767T3 (en) 2019-04-29
EA032512B1 (ru) 2019-06-28
AU2016252237A1 (en) 2017-10-05
GB201507048D0 (en) 2015-06-10
JP2018520984A (ja) 2018-08-02
EA201792123A1 (ru) 2018-03-30
TR201905392T4 (tr) 2019-05-21
JP2021073257A (ja) 2021-05-13
EP3285767B8 (en) 2019-05-22
PT3285767T (pt) 2019-05-20
ZA201705847B (en) 2020-03-25

Similar Documents

Publication Publication Date Title
PH12017502297A1 (en) Antibacterial compounds
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
MY187540A (en) Compounds active towards bromodomains
PH12015502788A1 (en) Antibody formulations and methods
GB2541571A (en) Pharmaceutical compositions
MX2017013047A (es) Tratamiento de dolor.
PH12020500371A1 (en) Spirocycle compounds and methods of making and using same
CL2015002897A1 (es) Inhibidores de bace1
MD20160007A2 (ro) Inhibitori ai RORC2 şi metode de utilizare a acestora
TR201901348T4 (tr) Metap-2 inhibitörleri olarak pirolidinon türevleri.
PH12020500372A1 (en) Spirocycle compounds and methods of making and using same
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX2021010886A (es) Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson.
MX2017000306A (es) Metodos para tratar hipotension.
PH12016501838A1 (en) Compounds and their methods of use
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
ZA201907017B (en) Combination therapy for use in treating retroviral infection
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
IL268265B (en) 3-beta-hydroxy-5-alpha-paragnane-20-one for use in medical treatment
UA115417U (xx) Спосіб профілактики та лікування гіпоксичних змін при карбоперитонеумі
MX2017001512A (es) Compuestos activos hacia bromodominios.
GB2546703A (en) Compounds
MA39718A (fr) Compositions et méthodes d'utilisation de celles-ci
UA100460U (uk) Застосування препарату ноофен як засобу лікування еректильної дисфункції в моно- або комплексній терапії